Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Publication date: October 2020Source: The Lancet Neurology, Volume 19, Issue 10Author(s): Wim M Mulleners, Byung-Kun Kim, Miguel J A Láinez, Michel Lanteri-Minet, Patricia Pozo-Rosich, Shufang Wang, Antje Tockhorn-Heidenreich, Sheena K Aurora, Russell M Nichols, Laura Yunes-Medina, Holland C Detke

Source: The Lancet Neurology - September 17, 2020 Category: Neurology Source Type: research